Exact Sciences Corporation (EXAS) Earning Somewhat Positive Press Coverage, Report Finds
Media coverage about Exact Sciences Corporation (NASDAQ:EXAS) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Exact Sciences Corporation earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave news stories about the medical research company an impact score of 46.0466638846185 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the news stories that may have effected Accern’s analysis:
- Exact Sciences Corporation (EXAS) Short Interest Update (americanbankingnews.com)
- Analysts Expect Exact Sciences Corporation (NASDAQ:EXAS) to Post -$0.33 Earnings Per Share (americanbankingnews.com)
- Better Buy: Exact Sciences Corporation vs. Opko Health (fool.com)
- ETFs with exposure to EXACT Sciences Corp. : August 8, 2017 (finance.yahoo.com)
Exact Sciences Corporation (EXAS) opened at 37.76 on Friday. The firm’s market cap is $4.50 billion. Exact Sciences Corporation has a 52 week low of $13.05 and a 52 week high of $42.18. The firm’s 50 day moving average price is $37.62 and its 200-day moving average price is $28.82.
Exact Sciences Corporation (NASDAQ:EXAS) last posted its earnings results on Tuesday, July 25th. The medical research company reported ($0.27) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.10. The firm had revenue of $57.65 million during the quarter, compared to the consensus estimate of $47.73 million. Exact Sciences Corporation had a negative return on equity of 36.36% and a negative net margin of 83.08%. On average, analysts forecast that Exact Sciences Corporation will post ($1.18) EPS for the current year.
EXAS has been the topic of a number of research analyst reports. Vetr cut Exact Sciences Corporation from a “hold” rating to a “sell” rating and set a $34.70 target price on the stock. in a report on Wednesday, July 12th. Canaccord Genuity lifted their target price on Exact Sciences Corporation from $38.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, May 31st. Zacks Investment Research upgraded Exact Sciences Corporation from a “hold” rating to a “buy” rating and set a $39.00 target price on the stock in a report on Tuesday, June 27th. Roth Capital lifted their target price on Exact Sciences Corporation from $40.00 to $46.00 and gave the company a “buy” rating in a report on Wednesday, July 26th. Finally, Goldman Sachs Group, Inc. (The) set a $33.00 target price on Exact Sciences Corporation and gave the company a “neutral” rating in a report on Monday, May 1st. Six research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Exact Sciences Corporation currently has a consensus rating of “Buy” and a consensus price target of $40.51.
In other news, CFO Jeffrey Thomas Elliott sold 5,846 shares of the stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $39.41, for a total transaction of $230,390.86. Following the completion of the transaction, the chief financial officer now directly owns 19,861 shares in the company, valued at approximately $782,722.01. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP D Scott Coward sold 1,987 shares of the stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $35.21, for a total value of $69,962.27. Following the transaction, the senior vice president now owns 57,603 shares of the company’s stock, valued at $2,028,201.63. The disclosure for this sale can be found here. 4.00% of the stock is currently owned by corporate insiders.
About Exact Sciences Corporation
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.